• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿激酶纤溶酶原激活物与其受体的结合:在具有应用于 uPA-uPAR 肽抑制剂的非均匀介电函数框架内的量子生物化学描述。

The urokinase plasminogen activator binding to its receptor: a quantum biochemistry description within an in/homogeneous dielectric function framework with application to uPA-uPAR peptide inhibitors.

机构信息

Instituto Federal de Educação, Ciência e Tecnologia do Ceará, Campus Horizonte, Horizonte, CE, Brazil.

Departamento de Ciências Naturais, Matemática e Estatística, Universidade Federal Rural do Semi-Árido, Mossoró, RN, Brazil.

出版信息

Phys Chem Chem Phys. 2020 Feb 14;22(6):3570-3583. doi: 10.1039/c9cp06530j. Epub 2020 Jan 29.

DOI:10.1039/c9cp06530j
PMID:31995079
Abstract

Despite being recognized as a therapeutic target in the processes of cancer cell proliferation and metastasis for over 50 years, the interaction of the urokinase plasminogen activator uPA with its receptor uPAR still needs an improved understanding. High resolution crystallographic data (PDB ) of the uPA-uPAR binding geometry was used to perform quantum biochemistry computations within the density functional theory (DFT) framework. A divide to conquer methodology considering a mixed homogeneous/inhomogeneous dielectric model and explicitly taking water molecules into account was employed to obtain a large set of uPA-uPAR residue-residue interaction energies. In order of importance, not only were Phe25 > Tyr24 > Trp30 > Ile28 shown to be the most relevant uPA residues binding it to uPAR, but the residues Lys98 > His87 > Gln40 > Asn22 > Lys23 > Val20 also had significant interaction energies, which helps to explain published experimental mutational data. Furthermore, the results obtained with the uPA-uPAR in/homogeneous dielectric function show that a high dielectric constant value ε = 40 is adequate to take into account the electrostatic environment at the interface between the proteins, while using a smaller value of ε (<10) leads to an overestimation of the uPA-uPAR binding energy. Hot spots of the uPA-uPAR binding domain were identified and a quantum biochemistry description of the uPAR blockers uPA and cyclouPA[(S21C;H29C)] was performed, demonstrating that cyclization improves the stability of mimetic peptides without compromising their binding energies to uPAR.

摘要

尽管尿激酶型纤溶酶原激活物 uPA 与其受体 uPAR 的相互作用在癌症细胞增殖和转移过程中被认为是一个治疗靶点已经超过 50 年,但人们对其仍需要进一步了解。利用 uPA-uPAR 结合几何结构的高分辨率晶体学数据(PDB ),在密度泛函理论(DFT)框架内进行量子生物化学计算。采用一种分而治之的方法,考虑混合均匀/不均匀介电模型,并明确考虑水分子,以获得大量的 uPA-uPAR 残基-残基相互作用能。按重要性顺序,不仅显示 Phe25 > Tyr24 > Trp30 > Ile28 是与 uPAR 结合的最相关的 uPA 残基,而且 Lys98 > His87 > Gln40 > Asn22 > Lys23 > Val20 残基也具有显著的相互作用能,这有助于解释已发表的实验突变数据。此外,使用 uPA-uPAR 均匀/非均匀介电函数获得的结果表明,高介电常数值 ε = 40 足以考虑蛋白质之间界面的静电环境,而使用较小的 ε 值(<10)会导致 uPA-uPAR 结合能的高估。确定了 uPA-uPAR 结合域的热点,并对 uPA 和环乌帕[(S21C;H29C)]uPAR 阻断剂进行了量子生物化学描述,证明环化提高了模拟肽的稳定性,而不会影响其与 uPAR 的结合能。

相似文献

1
The urokinase plasminogen activator binding to its receptor: a quantum biochemistry description within an in/homogeneous dielectric function framework with application to uPA-uPAR peptide inhibitors.尿激酶纤溶酶原激活物与其受体的结合:在具有应用于 uPA-uPAR 肽抑制剂的非均匀介电函数框架内的量子生物化学描述。
Phys Chem Chem Phys. 2020 Feb 14;22(6):3570-3583. doi: 10.1039/c9cp06530j. Epub 2020 Jan 29.
2
Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.人尿激酶型纤溶酶原激活剂受体结合区域的系统突变分析
Eur J Biochem. 1996 May 1;237(3):743-51. doi: 10.1111/j.1432-1033.1996.0743p.x.
3
The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.氨基酸突变对尿激酶型纤溶酶原激活物与其受体之间特定相互作用的影响:从头算分子轨道计算。
J Mol Graph Model. 2011 Aug;29(8):975-84. doi: 10.1016/j.jmgm.2011.04.003. Epub 2011 Apr 16.
4
High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.抑制尿激酶/尿激酶受体相互作用的高亲和力尿激酶衍生环肽:对肿瘤生长和扩散的影响。
FEBS Lett. 2002 Sep 25;528(1-3):212-6. doi: 10.1016/s0014-5793(02)03311-2.
5
Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.人尿激酶型纤溶酶原激活剂与其受体的结合:涉及物种特异性和结合的残基。
Arterioscler Thromb Vasc Biol. 1998 May;18(5):693-701. doi: 10.1161/01.atv.18.5.693.
6
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.使用四硝基甲烷对尿激酶型纤溶酶原激活剂及其受体进行化学修饰。受体-配体相互作用过程中两个分子中特定酪氨酸残基参与作用的证据。
Biochemistry. 1995 Oct 3;34(39):12524-34. doi: 10.1021/bi00039a006.
7
Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.尿激酶型纤溶酶原激活剂与其受体之间特定相互作用的从头算分子轨道计算。
J Mol Graph Model. 2009 Aug;28(1):46-53. doi: 10.1016/j.jmgm.2009.04.001. Epub 2009 Apr 9.
8
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.尿激酶型纤溶酶原激活剂(uPA)衍生的受体结合域模拟物的合成、溶液结构及生物学评价
J Med Chem. 2002 Nov 7;45(23):4984-94. doi: 10.1021/jm020254q.
9
Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.小分子通过协同结合作用于热点区域以抑制紧密的蛋白质-蛋白质相互作用。
Biochemistry. 2017 Mar 28;56(12):1768-1784. doi: 10.1021/acs.biochem.6b01039. Epub 2017 Mar 17.
10
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.尿激酶型纤溶酶原激活剂-二氧化硅颗粒(SP-uPA):一种用于研究尿激酶型纤溶酶原激活剂-尿激酶型纤溶酶原激活剂受体相互作用以及测试合成的尿激酶型纤溶酶原激活剂受体拮抗剂作为潜在癌症治疗药物的新型分析系统。
Biol Chem. 2002 Jan;383(1):207-16. doi: 10.1515/BC.2002.021.

引用本文的文献

1
Alzheimer's Disease Immunotherapy and Mimetic Peptide Design for Drug Development: Mutation Screening, Molecular Dynamics, and a Quantum Biochemistry Approach Focusing on Aducanumab::Aβ2-7 Binding Affinity.用于药物开发的阿尔茨海默病免疫疗法与模拟肽设计:聚焦阿杜卡努单抗与Aβ2-7结合亲和力的突变筛选、分子动力学及量子生物化学方法
ACS Chem Neurosci. 2024 Oct 2;15(19):3543-3562. doi: 10.1021/acschemneuro.4c00453. Epub 2024 Sep 20.
2
Investigation of protein-protein interactions and hotspot region on the NSP7-NSP8 binding site in NSP12 of SARS-CoV-2.新型冠状病毒(SARS-CoV-2)NSP12中NSP7-NSP8结合位点的蛋白质-蛋白质相互作用及热点区域研究
Front Mol Biosci. 2024 Jan 18;10:1325588. doi: 10.3389/fmolb.2023.1325588. eCollection 2023.
3
Quantum Biochemistry and MM-PBSA Description of the ZIKV NS2B-NS3 Protease: Insights into the Binding Interactions beyond the Catalytic Triad Pocket.
量子生物化学和 MM-PBSA 对 ZIKV NS2B-NS3 蛋白酶的描述:催化三联体口袋之外的结合相互作用的深入了解。
Int J Mol Sci. 2022 Sep 3;23(17):10088. doi: 10.3390/ijms231710088.
4
Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease.量子生物化学、分子对接和动力学模拟揭示了合成肽诱导的构象变化,影响了 SARS-CoV-2 主蛋白酶催化位点的拓扑结构。
J Biomol Struct Dyn. 2022;40(19):8925-8937. doi: 10.1080/07391102.2021.1920464. Epub 2021 May 5.